Active Pharmaceutical Ingredients (APIs)

  • Sacubitril-Valsartan*

    • API Product   :   

      Sacubitril-Valsartan*

    • CEP   :   

      -

    • WCC   :   

      -

    • Therapeutic Use    :   

      Urologicals; Other cardiovascular products

    • Originator   :   

      Novartis

    • CAS No.    :   

      936623-90-4

    • Trade Name.   :   

      Entresto, Azmarda

    • Molecular Weight   :   

      1916.018 g/mol

    • Molecular Formula   :   

      C96H120N12Na6O21

    Application

    Valsartan is an angiotensin II receptor blocker (sometimes called an ARB). Valsartan keeps blood vessels from narrowing, which lowers blood pressure and improves blood flow. Sacubitril and valsartan is a combination medicine used in certain people with chronic heart failure.

    General Description

    Sacubitril/valsartan, sold under the brand name Entresto among others, is a combination drug for use in heart failure developed by Novartis. It consists of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker valsartan, in a 1:1 mixture by molecule count. It is recommended for use as a replacement for an ACE inhibitor or an angiotensin receptor blocker in people with heart failure with reduced ejection fraction.[1] Potential side effects include angioedema, kidney problems, and low blood pressure.[1] The risk of kidney problems and increased levels of serum potassium with sacubitril/valsartan is lower than that of an ACE inhibitor or angiotensin receptor blocker. The combination is sometimes described as an "angiotensin receptor-neprilysin inhibitor".